The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous
- PMID: 31423583
- DOI: 10.1002/ijc.32631
The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous
Comment in
-
Author's reply to: The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous.Int J Cancer. 2019 Dec 1;145(11):3175-3176. doi: 10.1002/ijc.32630. Epub 2019 Sep 3. Int J Cancer. 2019. PMID: 31423580 No abstract available.
Comment on
-
Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.Int J Cancer. 2020 Jan 1;146(1):26-34. doi: 10.1002/ijc.32229. Epub 2019 Mar 20. Int J Cancer. 2020. PMID: 30801710 Free PMC article.
References
-
- Verver D, van der Veldt A, van Akkooi A, et al. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a Dutch population-based study. Int J Cancer 2019. https://doi.org/10.1002/ijc.32229. [Epub ahead of print].
-
- Donia M, Ellebaek E, Øllegaard TH, et al. The real-world impact of modern treatments on the survival of patients with metastatic melanoma. Eur J Cancer 2019;108:25-32.
-
- de Waal AC, Aben KKH, van Rossum MM, et al. Melanoma of unknown primary origin: a population-based study in The Netherlands. Eur J Cancer 2013;49:676-83.
-
- Prens SP, van der Ploeg APT, van Akkooi ACJ, et al. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol 2011;18:3586-92.
-
- Lee CC, Faries MB, Wanek LA, et al. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009;27:3489-95.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
